Business Context and Reporting Period
This Form 8-K was filed by Cerecor Inc. (trading symbol: CERC) on March 25, 2021. The filing reports the entry into a Material Definitive Agreement involving the Company's wholly-owned subsidiary, Aevi Genomic Medicine, LLC. The Company is a Delaware corporation focused on developing treatments for neurological disorders.
Key Financial Metrics and Agreement Terms
The filing details a new License Agreement with Kyowa Kirin Co., Ltd. (KKC) regarding CERC-002, a first-in-class fully human anti-LIGHT monoclonal antibody. Key financial terms include:
- Upfront Payment: The Company will pay KKC an upfront license fee of $10 million.
- Milestone Payments: Aevi will pay KKC success-based regulatory milestones totaling mid-teen millions of dollars or less per indication for three separate indications, depending on territory.
- Royalties: Aevi will pay KKC royalties equal to a mid-teens percentage of net sales of CERC-002 on a country-by-country basis.
- Sublicensing: Aevi will pay KKC a double-digit percentage (less than 30%) of payments received from sublicensing rights.
The filing text does not provide specific values for the Company's current revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Strategic Shifts
This agreement replaces the Amended and Restated Clinical Development and Option Agreement (CDOA) dated May 28, 2020. Under the new terms, the Company secures exclusive worldwide rights to develop, manufacture, and commercialize CERC-002 for all indications, subject to a specific option for Japan. This represents a shift from the previous arrangement to a definitive licensing structure with defined upfront and contingent costs.
Outlook, Risks, and Contingencies
Japan Option: The Company granted KKC an option to exclude Japan from the worldwide rights. If exercised, KKC would handle development and commercialization in Japan. Upon exercise, KKC must reimburse the Company for a pre-agreed percentage of certain development costs, pay for services, cover further development in Japan, and pay royalties to the Company's licensors. No additional license fees or milestones would be payable by KKC to the Company for Japan.
Expiration of Option: The Japan option expires if KKC does not exercise it within a set number of days after the FDA accepts a Biologics License Application for a pre-defined indication.
Confidentiality: The Company intends to seek confidential treatment for certain terms of the License Agreement when filing the full text as an exhibit to its Form 10-Q for the quarter ending March 31, 2021.
Investor Verification Checklist
- Verify the impact of the $10 million upfront payment on the Company's cash position and liquidity.
- Review the upcoming Form 10-Q for the full text of the License Agreement to understand confidential terms.
- Monitor the status of the FDA Biologics License Application for CERC-002, as this triggers the expiration of the Japan option.
- Assess the Company's ability to fund the mid-teen million dollar milestone payments and ongoing royalty obligations.
- Confirm the specific pre-agreed percentage for cost reimbursement should KKC exercise the Japan option.